0 results

Patient Corner

Anatomical Illustrations

More

Latest drug updates

  • 28 Apr 2017 - Drug Updates

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

HCPs advised to report adverse effects associated with fingolimod (Gilenya▼) or other treatments for multiple sclerosis.

Read more
  • 28 Apr 2017 - Drug Updates

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Valproate should not be prescribed to women and girls of childbearing potential unless other treatments are ineffective or not tolerated.

Read more
  • 28 Apr 2017 - Drug Updates

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

Dose reduction of ponatinib to 15 mg a day can decrease the risk of vascular arterial occlusion.

Read more
  • 23 Mar 2017 - Drug Updates

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

Close monitoring in patients with uncontrolled diabetes and comorbidities like heart and blood vessel events.

Read more
  • 23 Mar 2017 - Drug Updates

Pilot website to report adverse reactions of psychoactive substances

Illicit drug reaction reporting form made available for healthcare professionals,

Read more
  • 8 Mar 2017 - Drug Updates

Hyoscine butylbromide: serious adverse effects in cardiac patients

9 fatalities have been reported so far.

Read more
  • 16 Sep 2016 - Drug Updates

Idelalisib (Zydelig▼): updated safety information on risk of infection

Treatment recommendations for idelalisib have been updated following conclusion of safety review

Read more
  • 16 Sep 2016 - Drug Updates

Posaconazole (Noxafil): tablets and oral suspension not interchangable

Different dosage forms of posaconazole should not be substituted for each other

Read more
  • 16 Sep 2016 - Drug Updates

Levonorgestrel-containing emergency contraceptives: interaction with hepatic enzyme inducers

Concomitant CYP3A4 enzyme inducers reduce the efficacy of levonorgestrel

Read more
  • 10 Aug 2016 - Drug Updates

Lonsurf ▼(trifluridine/tipiracil) approved for colorectal cancer chemotherapy

Lonsurf has been approved in the UK for treatment of metastatic colorectal cancer

Read more